| Biomarker ID | 1183 |
| PMID | 23896626 |
| Year | 2013 |
| Biomarker | Methylation Status of CYB5R2 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in PCa (β atleast ≥ 0.2) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Cytochrome P450 pathway |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | For analysis, 29 Normal, 7 HGPIN (High Grade Prostatic Intraepithelial Neoplasia) and 23 PCa tissue samples were included |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p =0.0003 |
| Method Used | EZ DNA Methylation Gold kit |
| Clinical | No |
| Remarks | The β-value is a continuous variable ranging between 0 and 1, representing the ratio of the intensity of the methylated-probe signal to the total locus signal intensity |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | CYB5R2 |